Gaurang Shah of Geojit Financial Services told CNBC-TV18, "We don't have specific coverage on Venus Remedies, but in the similar category we have a coverage on Granules India from a long-term perspective. So, my sense is that possibly Granules India is a better choice."
Granules India ended at Rs 142.20, up Rs 3.65, or 2.63 percent on the BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!